Faron Pharmaceuticals Oy (LON:FARN) Sets New 12-Month Low - Should You Sell?

Key Points

• 52-week low: Faron Pharmaceuticals' shares hit a new 52-week low of GBX 41 on Monday and last traded at GBX 43.77 with 145,928 shares changing hands.
• Key financial and technical indicators look weak: current ratio 0.84, quick ratio 1.09, debt-to-equity -133.35, 50-day SMA GBX 102.03 vs 200-day SMA GBX 155.61, market cap £50.68M and a negative P/E of -1.62.
• Insider and pipeline note: insider Jurriaan Dekkers sold 4,000 shares at GBX 182 (insiders own 3.94%), while the company remains a clinical-stage biopharma developing Clevegen (bexmarilimab), an anti-Clever-1 antibody candidate.

Faron Pharmaceuticals Oy (LON:FARN - )'s share price hit a new 52-week low during mid-day trading on Monday . The company traded as low as GBX 41 and last traded at GBX 43.77, with a volume of 145928 shares trading hands. The stock had previously closed at GBX 43.

Faron Pharmaceuticals Oy Price Performance

The company has a current ratio of 0.84, a quick ratio of 1.09 and a debt-to-equity ratio of -133.35. The company has a 50 day simple moving average of GBX 102.03 and a 200 day simple moving average of GBX 155.61. The stock has a market cap of £50.68 million, a P/E ratio of -1.62 and a beta of 1.09.

Insider Activity

In related news, insider Jurriaan Dekkers sold 4,000 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of GBX 182, for a total transaction of £7,280. 3.94% of the stock is owned by company insiders.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.